Sarcoma (Jan 2004)

A Phase II Study of Docetaxel for the Treatment of Recurrent Osteosarcoma

Anne Mctiernan,
Jeremy S. Whelan

Affiliations

Anne Mctiernan: Meyerstein Institute of Oncology, Middlesex Hospital, UCL Hospitals NHS Trust, Mortimer St, London W1T 3AA, UK
Jeremy S. Whelan: Meyerstein Institute of Oncology, Middlesex Hospital, UCL Hospitals NHS Trust, Mortimer St, London W1T 3AA, UK

DOI: https://doi.org/10.1155/2004/762736
Journal volume & issue: Vol. 8, no. 2-3
pp. 71 – 76

Abstract

Purpose: To determine the response and toxicity of docetaxel in recurrent osteosarcoma and related spindle cell tumours of bone.

Published in Sarcoma

ISSN: 1357-714X (Print); 1369-1643 (Online)
Publisher: Hindawi Limited
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.hindawi.com/journals/sarcoma/

About the journal